Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
暂无分享,去创建一个
J. Uchida | Hidekazu Suzuki | Y. Fukuda | K. Hirano | T. Yokoyama | M. Tamiya | A. Tamiya | H. Tomioka | D. Fujimoto | S. Hara | M. Kanazu | M. Morita | Ryota Kominami | Shuji Yamashita